Books on the topic 'PNEUMOCOCCO'

To see the other types of publications on this topic, follow the link: PNEUMOCOCCO.

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'PNEUMOCOCCO.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Siber, George R., Keith P. Klugman, and P. Helena Mäkelä, eds. Pneumococcal Vaccines. Washington, DC, USA: ASM Press, 2008. http://dx.doi.org/10.1128/9781555815820.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Tuomanen, Elaine I., Timothy J. Mitchell, Donald Morrison, and Brian G. Spratt, eds. The Pneumococcus. Washington, DC, USA: ASM Press, 2004. http://dx.doi.org/10.1128/9781555816537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

I, Tuomanen Elaine, ed. The pneumococcus. Washington, DC: ASM Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

King, Samantha Jane. Epidemiology and evolution of pneumococcal neuraminidases. [s.l.]: typescript, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

T, Mayon-White Richard, and Royal Society of Medicine (Great Britain), eds. The clinical impact of pneumococcal disease and strategies for its prevention: Proceedings of an international conference sponsored by Pasteur Merieux MSD held at the Royal Society of Medicine, London, 13 December 1994. London, UK: Royal Society of Medicine Press, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

R, Siber George, Klugman Keith P, and Mäkelä P. Helena, eds. Pneumococcal vaccines: The impact of conjugate vaccine. Washington, DC: ASM Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Riddiough, Michael A. Implications of alternative Medicare payment methods for pneumoccal vaccination. Washington, DC: Health Program, Office of Technology Assessment, U.S. Congress, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Riddiough, Michael A. Implications of alternative Medicare payment methods for pneumoccal vaccination. Washington, DC: Health Program, Office of Technology Assessment, U.S. Congress, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nuorti, J. Pekka. Prevention of pneumococcal disease among infants and children: Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP). Atlanta, GA: Dept. of Health and Human Services, Centers for Disease Control and Prevention, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Riddiough, Michael A. Implications of alternative Medicare payment methods for pneumoccal vaccination. Washington, DC: Health Program, Office of Technology Assessment, U.S. Congress, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Aging, National Institute on, ed. Pneumonia prevention: It's worth a shot. [Gaithersburg, MD]: National Institute of Aging, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Parker, James N., and Philip M. Parker. The official patient's sourcebook on pneumonia. San Diego, Calif: Icon Health Publications, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Life with the pneumococcus: Notes from the bedside, laboratory, and library. Philadelphia: University of Pennsylvania Press, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Centers for Medicare & Medicaid Services (U.S.), ed. Medicare preventive services: Adult immunizations : a guide to billing influenza and pneumococcal vaccinations. [Baltimore, Md.]: Centers for Medicare & Medicaid Services, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Siriwardena, Aloysius Niroshan. The impact of educational interventions on influenza and pneumococcal vaccination rates in primary care. Leicester: De Montfort University, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Travers, Jasmine. Infection Control and Racial/Ethnic Disparities in Influenza and Pneumococcal Vaccination in Nursing Homes. [New York, N.Y.?]: [publisher not identified], 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

Paul, John. Microbiological aspects of pneumococcal disease in patients infected with human immunodeficiency virus in Nairobi, Kenya. Birmingham: University of Birmingham, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Pneumonia before antibiotics: Therapeutic evolution and evaluation in twentieth-century America. Baltimore: Johns Hopkins University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

Office, General Accounting. Immunization: HHS could do more to increase vaccination among older adults : report to Congressional requesters. Washington, D.C: The Office, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Officer, Great Britain Department of Health Chief Medical. Adult immunisation update: (i) introduction of a pneumococcal immunisation programme for those aged 80 years and over : (ii) influenza immunisation programme 2003/2004. London: Department of Health, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

New York Academy of Sciences. Pharmaceutical science to improve the human condition: Prix Galien 2011 : winners and finalist candidate of the Prix Galien USA Awards 2011. Malden, MA: Wiley Periodicals, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Spratt, Brian G., Donald Morrison, Elaine I. Tuomanen, and Timothy J. Mitchell. Pneumococcus. Wiley & Sons, Limited, John, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

The pneumococcus. Washington, DC: ASM Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

(Editor), Elaine I. Tuomanen, Timothy J. Mitchell (Editor), Donald Morrison (Editor), and Brian G. Spratt (Editor), eds. The Pneumococcus. ASM Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Pneumococcal Infections. Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

CALDERA, David. Prevnar (pneumococcal). Independently Published, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

Bai, Guangchun, and Jorge Eugenio Vidal, eds. Molecular Pathogenesis of Pneumococcus. Frontiers Media SA, 2017. http://dx.doi.org/10.3389/978-2-88945-278-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Yamaguchi, Masaya, Yuki Kinjo, and Victor Nizet. Host-pathogen Interaction During Pneumococcal Infections. Frontier Media SA, 2021. http://dx.doi.org/10.3389/978-2-88971-888-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

The Clinical Impact of Pneumococcal Disease And Strategies for Its Prevention (International Congress & Symposium). Royal Society of Medicine Press Ltd, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

Mäkelä, P. Helena, George R. Siber, and Keith P. Klugman. Pneumococcal Vaccines: The Impact of Conjugate Vaccines. Wiley & Sons, Limited, John, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Kumar, Deepali. Immunogenicity of pneumococcal vaccination in renal transplant recipients. 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Jeurissen, Axel. Regulation of the Antibody Response to Pneumococcal Capsular Polysaccharides. Leuven Univ Pr, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Pneumococcal Vaccines - Recent Advances, New Perspectives and Applications [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.102200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Weinberger, Daniel Martin. Factors affecting the carriage and disease patterns of pneumococcal serotypes. 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Implementation of Vaccine Policy (International Congress and Symposium). Royal Society of Medicine Press, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Peters, Jennifer Ann. FOSTERING INFLUENZA AND PNEUMOCOCCAL IMMUNIZATION: A NURSING INTERVENTION FOR OLDER ADULTS. 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Watson, D. The Pneumococcus: Epidemology, Prophylaxis, Treatment and Virulence (Medical Intelligence Unit Series). R. G. Landes, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Austrian, Robert, and Lewis Thomas. Life with the Pneumococcus: Notes from the Bedside, Laboratory, and Library. University of Pennsylvania Press, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Vu, Kathy. Understanding the factors affecting influenza and pneumococcal vaccination in cardiac patients. 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
40

van Assen, Sander, and Marc Bijl. Vaccination in immunocompromised adults. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0094.

Full text
Abstract:
This chapter addresses all important questions regarding vaccination of patients with autoimmune inflammatory rheumatic diseases (AIIRD). First, the incidence of vaccine-preventable infections in these patients is discussed. Pulmonary infections, including influenza and pneumococcal infection, occur more often in AIIRD patients; herpes zoster and human papillomavirus are also more frequent. The efficacy of vaccination for all European registered vaccines is discussed. Treatment with disease-modifying anti-rheumatic drugs (DMARDs) and biologicals (in particular TNFα‎-blocking agents) do not hamper, or only slightly hamper, the immune responses to most vaccines. Rituximab is an exception, severely reducing humoral responses following influenza and pneumococcal vaccination, at least during the first 6 months after administration. Safety of vaccination is an important issue in patients with autoimmune diseases, since increased disease activity of the underlying disease as a result of vaccination is theoretically possible. The available evidence is summarized, suggesting that vaccination is safe in AIIRD patients. Live vaccines, however, are contraindicated in immunosuppressed patients with AIIRD. Finally, the European League Against Rheumatism (EULAR) recommendations are highlighted, summarizing the 'do's' and 'don'ts' of vaccination in adults with AIIRD.
APA, Harvard, Vancouver, ISO, and other styles
41

Harrison, Mark. Principles of immunization. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198765875.003.0012.

Full text
Abstract:
This chapter describes the principles of microbiology immunization as they apply to Emergency Medicine, and in particular the Primary FRCEM examination. The chapter outlines the key details of immunization schedules for diphtheria, tetanus, pertussis, Haemophilus influenzae type b, polio, Pneumococcal infection, MMR, meningitis C, HPV, varicella, hepatitis B, and influenza, as well as further sources of information. This chapter is laid out exactly following the RCEM syllabus, to allow easy reference and consolidation of learning.
APA, Harvard, Vancouver, ISO, and other styles
42

The Biology of Pneumococcus; the Bacteriological, Biochemical, and Immunological Characters and Activities of Diplococcus Pneumoniae. Franklin Classics, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

MD, Benjamin White, Elliott Stirling Robinson, and Laverne Almon Barnes. The Biology of Pneumococcus; The Bacteriological, Biochemical, and Immunological Characters and Activities of Diplococcus Pneumoniae. Franklin Classics Trade Press, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

MD, Benjamin White, Elliott Stirling Robinson, and Laverne Almon Barnes. The Biology of Pneumococcus; The Bacteriological, Biochemical, and Immunological Characters and Activities of Diplococcus Pneumoniae. Franklin Classics Trade Press, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Podolsky, Scott H. Pneumonia Before Antibiotics: Therapeutic Evolution and Evaluation in Twentieth-Century America. Johns Hopkins University Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Immunization: HHS could do more to increase vaccination among older adults : report to Congressional requesters. Washington, D.C. (P.O. Box 37050, Washington 20013): The Office, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
47

Torres, Antoni, and Adamantia Liapikou. Diagnosis and management of community-acquired pneumonia. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0116.

Full text
Abstract:
Severe community-acquired pneumonia (SCAP) remains the most common infectious reason for admission to the intensive care unit (ICU), reaching a mortality rate of 30–40%. The microbial pattern of the SCAP has changed with S. pneumoniae still the leading pathogen, but a decrease of atypical pathogens, especially Legionella and an increase of viral and polymicrobial pneumonias. IDSA/ATS issued guidelines on the management of CAP including specific criteria to identify patients for ICU admission with good predictive value. The first selection of antimicrobial therapy should be started early covering all likely pathogens, depending on the presence of the risk factors for Pseudomonas aeruginosa infection. Combination therapy may be useful in patients with non-refractory septic shock and severe sepsis pneumococcal bacteraemia as well. The challenges include the emergence of new pathogens as community-acquired methicillin-resistant Staphylococcus aureus, new influenza virus subtypes and the high prevalence of multidrug resistance, mainly from institutionalizing patients.
APA, Harvard, Vancouver, ISO, and other styles
48

Heijstek, Marloes, Mario Abinun, and Nico Wulffraat. Vaccination in immunocompromised children. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0095.

Full text
Abstract:
Can immunocompromised children be safely and effectively vaccinated? This chapter discusses the recommendations from the European League Against Rheumatism (EULAR) for the immunization of immunocompromised patients. Patients with rheumatic or autoinflammatory diseases treated with high-dose glucocorticoids, high-dose disease-modifying anti-rheumatic drugs (DMARDs), or biologicals are considered immunocompromised. Safe and effective vaccination is crucial in these patients, given their increased risk of infection. Safe vaccination implies that vaccination has no effect on disease activity and has only mild adverse effects. Effective vaccination denotes that patients are protected against infections after immunization. Particularly in severely immunosuppressed patients, concerns arise on the safety of (live-attenuated) vaccines and on the detrimental effect of immunosuppressive treatment on the immunogenicity of vaccines. Overall, vaccinations do not increase disease activity and do not cause severe adverse events. Although non-live vaccines are safe, it is recommended to withhold live-attenuated vaccines in patients on high-dose immunosuppressive drugs and biologicals. However, booster vaccinations can be considered when essential. Generally, immunogenicity of vaccines is good with some exceptions: responses are reduced in patients on high-dose glucocorticoids and rituximab; methotrexate reduces responses to (pneumococcal) polysaccharide vaccines; and anti-tumour necrosis factor alpha (TNFα‎) may lower vaccine-induced antibody concentrations. Offering vaccination before immunosuppressive drugs and/or measuring antibodies after immunization is recommended.
APA, Harvard, Vancouver, ISO, and other styles
49

Heijstek, Marloes, Mario Abinun, and Nico Wulffraat. Vaccination in immunocompromised children. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0095_update_003.

Full text
Abstract:
Can immunocompromised children be safely and effectively vaccinated? This chapter discusses the recommendations from the European League Against Rheumatism (EULAR) for the immunization of immunocompromised patients. Patients with rheumatic or autoinflammatory diseases treated with high-dose glucocorticoids, high-dose disease-modifying antirheumatic drugs (DMARDs), or biologicals are considered immunocompromised. Safe and effective vaccination is crucial in these patients, given their increased risk of infection. Safe vaccination implies that vaccination has no effect on disease activity and has only mild adverse effects. Effective vaccination denotes that patients are protected against infections after immunization. Particularly in severely immunosuppressed patients, concerns arise on the safety of (live-attenuated) vaccines and on the detrimental effect of immunosuppressive treatment on the immunogenicity of vaccines. Overall, vaccinations do not increase disease activity and do not cause severe adverse events. It is recommended to withhold live-attenuated vaccines in patients on high-dose immunosuppressive drugs and biologicals, but booster vaccinations can be considered when essential. Generally, immunogenicity of vaccines is good with some exceptions: responses are reduced in patients on high-dose glucocorticoids and rituximab; methotrexate reduces responses to (pneumococcal) polysaccharide vaccines; and tumour necrosis factor alpha (TNFα‎) may lower vaccine-induced antibody concentrations and may cause accelerated waning of immunity. Offering vaccination before immunosuppressive drugs and/or measuring antibodies after immunization is recommended.
APA, Harvard, Vancouver, ISO, and other styles
50

Tomasz, Alexander, ed. Streptococcus Pneumoniae: Molecular Biology & Mechanisms of Disease. MARY ANN LIEBERT PUBLISHING, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography